Intellia Therapeutics Inc. [NASDAQ:NTLA] prices rallied 13.18% on Wednesday.
With a current price of $23.78, NTLA is active in the Biotechnology industry and it looks to be on-track for a five-day run of 19.62%.
In addition, NTLA’s high over the last year is $25.56 and the low is $9.18. Over the last two 52 weeks, the company is trading 119.98%, while the S&P 500 is trading 1.71%.
The Price is right
Holding a Market Cap of $1.49 billion, Intellia Therapeutics Inc. has seen a trading range over the last year of $9.18-$25.56.
For the last five days, NTLA is up from its last closing price. The average shares trading hands each day is 755.79K.
Using a Force Index Indicator is a good way to look at how strong actual buying and selling pressure is for NTLA. When we apply the Elder Force Index to Intellia Therapeutics Inc., we are seeing an Elder Force Indicator number of 7429040.28.
In the last quarter, NTLA made a profit of 49.3 million. Intellia Therapeutics Inc. also saw quarter revenue growth year over year of 41.63%.
Looking at popular technical indicators, the company’s 5-day moving average is 20.90 compared to the 50-day moving average of 18.99%. So, we are clearly seeing an upward trajectory here.
The Relative Strength Index or RSI is an indicator ranging between 0 and 100 that traders use to determine if a stock is “overbought” or “oversold.” A strong uptrend tending to reach into the “overbought” status is above 70, while a downward trend will stay around the 30 mark. NTLA currently holds a 9-day RSI of 66.02%, while 100-day RSI stands at 53.93%.
Another indicator we believe is worth keeping tabs on is the Moving Average Convergence Divergence or MACD. Similar to the concept of the Force Index — on the basis of price momentum — the MACD gives traders a tool to measure the turning point of a stock even during rapid fluctuations in price. Buy and sell signals are determined by a stock’s relation to the zero line, so if a stock is above a zero line for many weeks it might be a “buy.” On the other hand, if a stock is below the zero line consistently, it might be one to stay away from. Also, if the MACD line reaches a peak and dips, its momentum may be waning. NTLA’s 9-day MACD is 0.91 and the company’s 100-day MACD stands at 1.17.
Another area that is important to analyze is insider moves and majority shareholders. While this is not always an error-free way to tell what the future holds for a stock, you can maybe gather important information from reading the tea leaves about who is buying and selling.
The major holders for this stock are 19.02% by insiders and 76.41% by institutions. Regarding institutional holdings, ARK Investment Management, LLC owns 19.41%, while the second top holder, Sumitomo Mitsui Trust Holdings, Inc., currently owns 10.55%.
Over the last six months, insiders have sold 5,615 with the most recent transaction from Rivera Jose E, EVP, General Counsel, with a sell at price 21.04 per share.
Overall, the recommended rating for NTLA is Moderate Buy. Currently, the company has 10 analysts watching the stock, and the average quarterly earnings estimate is -0.58. Quarterly revenue estimates are averaging 16.27M with the high estimate reaching 29.4M and the low at 5.4M.
To review, the current 1-year target estimate is sitting at 30.41, while the current price 23.78. Based on this, we expect the stock to rise considering the aforementioned fundamentals.